Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor

Postmortem brain examinations in Alzheimer’s disease (AD) reveal β-amyloid plaques, neurofibrillary tangles resulting from tau protein aggregation, and neuronal and synaptic loss, which collectively impair brain function. O-linked N-acetylglucosami-nidase (OGA) is an enzyme that removes O-linked β-N-acetylglucosamine (O-GlcNAc) from proteins including tau. In animal tauopathy models, OGA inhibition was shown to increase O-GlcNAc−tau levels, leading to reduced tau hyperphosphorylation and aggregation. These results inspired efforts to develop OGA inhibitors for the treatment of AD and tauopathies. Here we report the discovery and clinical development of ceperognastat (LY3372689), a low-dose, CNS-penetrant OGA inhibitor that has been evaluated in a completed phase II study in patients with early symptomatic AD.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-21
DOI
https://doi.org/10.1021/acs.jmedchem.6c02053
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor

Feiyu Fred Zhang, Hugh Norman Nuthall, Susan L. DuBois, Nicolas Dreyfus et al.
Journal of Medicinal Chemistry
Alzheimer's disease research and treatments
article

Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor

Feiyu Fred Zhang, Hugh Norman Nuthall, Susan L. DuBois, Nicolas Dreyfus, Peter J. Lindsay‐Scott, Sergey Shcherbinin, Jeremy Gilmore, Jörg Hendle, Eric M. Woerly, David A. Price Evans, William Kielbasa, Dustin J. Mergott, Kevin B. Donnelly, Leonard L. Winneroski, Michele Mancini, Paul Goldsmith, Richard E. Rathmell, Emily C. Collins, José Enrique López, Stephen Loucian Lowe, Adam S Fleisher, Michael Hutton
article en

Abstract

Postmortem brain examinations in Alzheimer’s disease (AD) reveal β-amyloid plaques, neurofibrillary tangles resulting from tau protein aggregation, and neuronal and synaptic loss, which collectively impair brain function. O-linked N-acetylglucosami-nidase (OGA) is an enzyme that removes O-linked β-N-acetylglucosamine (O-GlcNAc) from proteins including tau. In animal tauopathy models, OGA inhibition was shown to increase O-GlcNAc−tau levels, leading to reduced tau hyperphosphorylation and aggregation. These results inspired efforts to develop OGA inhibitors for the treatment of AD and tauopathies. Here we report the discovery and clinical development of ceperognastat (LY3372689), a low-dose, CNS-penetrant OGA inhibitor that has been evaluated in a completed phase II study in patients with early symptomatic AD.

Journal of Medicinal Chemistry
Eli Lilly (United States) (US), Eli Lilly (United Kingdom) (GB), Eli Lilly (Singapore) (SG), Eli Lilly (Italy) (IT)
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon